title: Induction of RIP-2 kinase by proinflammatory cytokines is mediated via NF-kappaB signaling pathways and involves a novel feed-forward regulatory mechanism.
abstract: The transcription factor NF-kappaB (nuclear factor kappaB) is a central mediator of inflammatory and apoptotic signaling in the cell. The protein kinase RIP-2 is a member of the CARD protein family (caspase activation and recruitment domain, also known as CARD3, Ripk2, CARDIAK, RICK, and CCK), and has been shown to be an activator of NF-kappaB. In this study, it was demonstrated by transcriptional profiling and protein expression analysis that the inflammatory cytokines TNF-alpha, IL-1 beta, and IFN-gamma induced RIP-2 transcription and translation in endothelial cells. Two mechanistically distinct inhibitors of NF-kappaB signaling, sulfasalazine (NF-kappaB inhibitor) and WY-14643 [PPAR alpha (peroxisome proliferator-activated receptor alpha) agonist] that interfere with the transcription factor RELA (p65), suppressed TNF-alpha induced RIP-2 gene expression, which indicated that NF-kappaB signaling was involved in the cytokine-induced transcriptional activation of RIP-2 gene expression. Consistent with these observations, multiple NF-kappaB response elements were found in the upstream regions of the human and mouse RIP-2 genes. NF-kappaB-mediated regulation of RIP-2 gene and protein expression suggests an additional step in the regulation of NF-kappaB function as RIP-2 has been shown to positively modulate NF-kappaB by binding IKK gamma (I kappaB kinase gamma), a component of the IKK complex. These findings support a positive feed-forward mechanism of NF-kappaB regulation that involves NF-kappaB-dependent induction of RIP-2 transcription and a subsequent increase in RIP-2 protein levels in response to inflammatory cytokines. Elevated RIP-2 protein levels are then available to promote NF-kappaB function via interaction with IKK gamma. RIP-2 is the first reported NF-kappaB-dependent protein kinase that positively regulates NF-kappaB activity.
authors.affiliation: Department of Medicine, St. Luke's and Roosevelt Hospital, 1111 Amsterdam Avenue, New York, NY 10025, USA. xixiyin2004@yahoo.com
authors.forename: Xixi
authors.initials: X
authors.lastname: Yin
authors.forename: Paul
authors.initials: P
authors.lastname: Krikorian
authors.forename: Thomas
authors.initials: T
authors.lastname: Logan
authors.forename: Vilmos
authors.initials: V
authors.lastname: Csizmadia
mesh_terms: D000818:Animals; D016207:Cytokines / Q000235:genetics / Q000502:physiology*; D025461:Feedback, Physiological; D006801:Humans; D051550:I-kappa B Kinase / Q000378:metabolism; D018836:Inflammation Mediators; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism*; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2 / Q000235:genetics*; D053422:Receptor-Interacting Protein Serine-Threonine Kinases / Q000235:genetics*; D015398:Signal Transduction; D015533:Transcriptional Activation
chemical_list: D016207:Cytokines; D018836:Inflammation Mediators; D016328:NF-kappa B; C506253:RIPK2 protein, human; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2; D053422:Receptor-Interacting Protein Serine-Threonine Kinases; C506255:Ripk2 protein, mouse; D051550:I-kappa B Kinase
references.citation: Mol Cell. 1998 Aug;2(2):275-81
references.pmid: 9734366
references.citation: Mol Endocrinol. 2002 May;16(5):1029-39
references.pmid: 11981037
references.citation: Nature. 2002 Mar 14;416(6877):194-9
references.pmid: 11894098
references.citation: Lipids. 2002 May;37(5):487-94
references.pmid: 12056591
references.citation: Gastroenterology. 2000 Nov;119(5):1209-18
references.pmid: 11054378
references.citation: Nature. 2002 Mar 14;416(6877):190-4
references.pmid: 11894097
references.citation: J Biol Chem. 1998 Jul 3;273(27):16968-75
references.pmid: 9642260
references.citation: J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):267-73
references.pmid: 12943712
references.citation: J Biol Chem. 1994 May 6;269(18):13551-7
references.pmid: 8175790
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2814-9
references.pmid: 11226323
references.citation: EMBO J. 1993 Jul;12(7):2773-9
references.pmid: 8334993
references.citation: J Interferon Cytokine Res. 1997 Mar;17(3):121-34
references.pmid: 9085936
references.citation: Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2094-104
references.pmid: 10479650
references.citation: Proc Natl Acad Sci U S A. 2003 May 27;100(11):6658-63
references.pmid: 12740434
references.citation: Biochem J. 2007 Jun 1;404(2):179-90
references.pmid: 17348859
references.citation: Science. 1997 Sep 12;277(5332):1630-5
references.pmid: 9287210
references.citation: Oncogene. 1999 Nov 22;18(49):6853-66
references.pmid: 10602461
references.citation: FASEB J. 2003 Dec;17(15):2187-93
references.pmid: 14656980
references.citation: J Biol Chem. 2001 Mar 2;276(9):6675-88
references.pmid: 11053426
references.citation: Oncogene. 1999 Nov 22;18(49):6845-52
references.pmid: 10602460
references.citation: J Biol Chem. 1999 Nov 5;274(45):32048-54
references.pmid: 10542237
references.citation: J Clin Invest. 1998 Mar 1;101(5):1163-74
references.pmid: 9486988
references.citation: J Biol Chem. 2000 Sep 8;275(36):27823-31
references.pmid: 10880512
references.citation: Pharmacol Ther. 1995 Feb;65(2):149-61
references.pmid: 7540766
references.citation: J Immunol. 2001 May 15;166(10):6170-80
references.pmid: 11342638
references.citation: Nat Rev Immunol. 2002 Oct;2(10):725-34
references.pmid: 12360211